ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Bladder Cancer

Bladder Cancer

In patients with stage II to III urothelial carcinoma, bladder-preservation therapy was associated with poorer overall survival compared with radical cystectomy, according to a database study.

Certain histologic variants of urothelial bladder cancer benefit more from neoadjuvant chemotherapy, according to a new study.

An immediate instillation of chemotherapy with mitomycin C following transurethral resection of a bladder tumor reduced the risk of recurrence of non–muscle-invasive bladder cancer (NMIBC).

A urine test of telomerase reverse transcriptase (TERT) was found to be a reliable predictor of recurrence in non–muscle-invasive bladder cancer, according to a new study.

Lack of participation in any regular recreational physical activity was associated with a significantly increased risk for both bladder and renal cancers.

After extended follow-up, the KEYNOTE-052 study has shown that first-line pembrolizumab offers durable responses and no new safety signals in patients with cisplatin-ineligible advanced urothelial cancer.

The combination of pembrolizumab and the IDO1 inhibitor epacadostat was active and generally well tolerated in patients with urothelial carcinoma.

Pages

Subscribe to Bladder Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.